SPIRIT for Persons With Dementia and Complex Multimorbidity
Primary Purpose
End Stage Renal Disease
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
SPIRIT-Dementia
Usual Care
Sponsored by
About this trial
This is an interventional supportive care trial for End Stage Renal Disease focused on measuring Dementia, Nursing, Nephrology, Behavioral research, Social research
Eligibility Criteria
Patient Inclusion Criteria:
- receiving in-center hemodialysis
- diagnosed with dementia or having mild to moderate cognitive impairment based on a Montreal Cognitive Assessment (MoCA) score 13-25 or a Saint Louis University Mental Status (SLUMS) score < 27 (high school education) or < 25 (less than high school education)
- able to understand and speak English
- a University of California San Diego Brief Assessment of Capacity to Consent (UBACC) score of 11 or higher
Exclusion Criteria:
- lack of an available surrogate
- uncompensated hearing deficits
- already enrolled in hospice
Surrogate Inclusion Criteria:
- 18 years or older
- be chosen by the patient
- able to understand and speak English
Sites / Locations
- Emory Dialysis at Northside
- Emory Dialysis at Greenbriar
- Emory Dialysis at North Decatur
- Emory Dialysis at Candler
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
SPIRIT-Dementia
Usual Care
Arm Description
Patients and their surrogates randomized to this study arm will receive the SPIRIT-dementia intervention.
Patients and surrogates randomized to this study arm will receive the standard information about advance directives that is provided at the time of diagnosis.
Outcomes
Primary Outcome Measures
Dyad Congruence
Dyad congruence will be assessed using the Goals-of-Care Tool which includes two scenarios describing medical conditions commonly occurring in ESRD patients. Possible responses to the scenarios are: "The goals of care should focus on delaying my death, and thus I want to continue life-sustaining treatment", "The goals of care should focus on my comfort and peace, and thus I do not want life-sustaining treatment, including dialysis", and "I am not sure". Patients and surrogates complete this tool independently and their responses are then compared to determine dyad congruence.
Patient's Decisional Conflict Scale (DCS) Score
Patient decisional conflict will be measured using the 13-item Decisional Conflict Scale (DCS), a validated measure in the context of end-of-life decision making. Participants indicate their level of agreement with statements about their plans for their future medical care by selecting (1) Strongly Agree, (2) Agree, (3) Neither Agree nor Disagree, (4) Disagree, or (5) Strongly Disagree. The total score ranges from 13 - 65 with higher scores indicating greater difficulty in weighing benefits and burdens of life-sustaining treatments and decision making.
Surrogate's Decision Making Confidence (DMC) Scale Score
Surrogate decision-making confidence will be measured using the 5-item Decision Making Confidence (DMC) scale. Surrogates indicate how confident they are about making medical decisions if the patient becomes unable to make their own decisions by their level of agreement with statements along a scale of (0) "Not confident at all" to (5) "Very confident". Total scores range from 0 - 20, with higher scores indicating greater confidence.
Secondary Outcome Measures
Care Decisions (Withdrawal From Dialysis, DNR, Hospice Enrollment)
The proportion of decisions (participants who withdrew from dialysis, Do not resuscitate (DNR), or chose hospice enrollment) will be compared between study arms.
Surrogate's Anxiety-Score Using the Hospital Anxiety and Depression Scale (HADS) Score
Surrogate post-bereavement anxiety and depressive symptoms will be measured with the Hospital Anxiety and Depression Scale (HADS). Surrogates indicate their level of agreement with statements by selecting responses rated from 0 (the problem in the statement is not an issue) to 3 (the problem in the statement is a very big issue). The separate anxiety and depression subscale scores range from 0 to 21 with higher scores indicating greater symptom severity. A score of 0-7 indicates "normal", 8-10 indicates "borderline abnormal", and 11-21 indicates "abnormal" levels of anxiety or depression.
Surrogate's Depression-Score by Using the Hospital Anxiety and Depression Scale (HADS) Score
Surrogate post-bereavement anxiety and depressive symptoms will be measured with the Hospital Anxiety and Depression Scale (HADS). Surrogates indicate their level of agreement with statements by selecting responses rated from 0 (the problem in the statement is not an issue) to 3 (the problem in the statement is a very big issue). The separate anxiety and depression subscale scores range from 0 to 21 with higher scores indicating greater symptom severity. A score of 0-7 indicates "normal", 8-10 indicates "borderline abnormal", and 11-21 indicates "abnormal" levels of anxiety or depression.
Full Information
NCT ID
NCT04108000
First Posted
September 26, 2019
Last Updated
April 27, 2023
Sponsor
Emory University
Collaborators
National Institute of Nursing Research (NINR), National Institute on Aging (NIA)
1. Study Identification
Unique Protocol Identification Number
NCT04108000
Brief Title
SPIRIT for Persons With Dementia and Complex Multimorbidity
Official Title
SPIRIT for Persons With Dementia and Complex Multimorbidity
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
February 14, 2020 (Actual)
Primary Completion Date
March 24, 2022 (Actual)
Study Completion Date
March 23, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Emory University
Collaborators
National Institute of Nursing Research (NINR), National Institute on Aging (NIA)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In this study, 30 patient and caregiver dyads will be randomized to receive the SPIRIT-dementia intervention or usual care. Participants will be follow-up with 2-3 days after the intervention to evaluate the impact of SPIRIT on preparedness outcomes. Additional follow up with caregivers will occur 6 months later.
Detailed Description
Cognitive impairment or dementia, usually vascular dementia or Alzheimer's, co-occur in approximately 38% of patients with end stage renal disease (ESRD). When dementia is superimposed on ESRD, the risk for poor outcomes, including disability, hospitalization and death, sharply increases. Similarly, initiating dialysis in older adults with multiple comorbidities, including dementia, does not offer survival benefit. However, advance care planning (ACP) discussions with dialysis patients rarely occur. The reality of ESRD plus dementia is that most of these patients are likely to die or progress to advanced dementia without ever engaging in ACP discussions before the cognitive window of opportunity closes. Moreover, persons with dementia (regardless of their cognitive impairment level) are routinely excluded from clinical trials of ACP, largely because investigators assume that these people do not have the cognitive capability to appreciate the complexity of ACP. In an on-going study ("SPIRIT in Dementia") the researchers carefully adapted SPIRIT for persons with mild to moderate dementia (mostly due to Alzheimer's) and their surrogates. In a sample of 23 dementia patients without complex multimorbidity and their surrogates, the researchers were able to conclude that meaningful ACP conversations were possible even for individuals with moderate dementia. Based on these findings, this supplement study will leverage the infrastructure of the parent SPIRIT in ESRD trial to pilot test the adapted SPIRIT intervention for patients with ESRD plus dementia as a model for determining whether patients with dementia superimposed on complex multimorbidity can fully participate in ACP discussion.
This purpose of this pilot randomized controlled trial with 30 patient and caregiver dyads is to:
estimate the effects of the SPIRIT-dementia intervention on: (a) preparedness outcomes for end-of-life decision making (defined as dyad congruence on goals of care, patient decisional conflict, and surrogate decision-making confidence) 2-3 days post-intervention, and (b) care decisions (withdrawal from dialysis, Do-Not-Resuscitate order, hospice enrollment) assessed at 6 months post-intervention, or the patient's death, whichever occurs first,
estimate the effects of the SPIRIT-dementia intervention on surrogates' post-bereavement distress (anxiety and depression symptoms) at 1 month after the patient's death, and
explore the relationships among patients' cognitive status, decision-making capacity and their ability to express end-of-life wishes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease
Keywords
Dementia, Nursing, Nephrology, Behavioral research, Social research
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
30 pairs of patients and their caregivers (surrogates) will be randomized to either receive the SPIRIT intervention or standard of care.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
38 (Actual)
8. Arms, Groups, and Interventions
Arm Title
SPIRIT-Dementia
Arm Type
Experimental
Arm Description
Patients and their surrogates randomized to this study arm will receive the SPIRIT-dementia intervention.
Arm Title
Usual Care
Arm Type
Active Comparator
Arm Description
Patients and surrogates randomized to this study arm will receive the standard information about advance directives that is provided at the time of diagnosis.
Intervention Type
Behavioral
Intervention Name(s)
SPIRIT-Dementia
Intervention Description
The interventionist will begin the SPIRIT-dementia session by assessing the patient's and surrogate's cognitive, emotional, and spiritual/religious representations of the patient's illness, prognosis, and end-of-life care. Individualized information will be provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the patient will examine their values about life-sustaining treatment at the end of life. The interventionist will help the surrogate prepare for end-of-life decision-making and for the emotional burden of decision-making. A Goals-of-Care document will be completed at the end of the session. The delivery of SPIRIT-dementia incorporates "enhanced consent techniques," such as reducing information load by proceeding in manageable segments, offering repetition of material, opportunity for rehearsal, and using targeted questioning to verify adequate comprehension prior to eliciting preferences for goals of care.
Intervention Type
Behavioral
Intervention Name(s)
Usual Care
Intervention Description
As required by Centers for Medicare and Medicaid Services (CMS) written information on advance directives is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an advance directive.
Primary Outcome Measure Information:
Title
Dyad Congruence
Description
Dyad congruence will be assessed using the Goals-of-Care Tool which includes two scenarios describing medical conditions commonly occurring in ESRD patients. Possible responses to the scenarios are: "The goals of care should focus on delaying my death, and thus I want to continue life-sustaining treatment", "The goals of care should focus on my comfort and peace, and thus I do not want life-sustaining treatment, including dialysis", and "I am not sure". Patients and surrogates complete this tool independently and their responses are then compared to determine dyad congruence.
Time Frame
Baseline, 2 Days Post-intervention
Title
Patient's Decisional Conflict Scale (DCS) Score
Description
Patient decisional conflict will be measured using the 13-item Decisional Conflict Scale (DCS), a validated measure in the context of end-of-life decision making. Participants indicate their level of agreement with statements about their plans for their future medical care by selecting (1) Strongly Agree, (2) Agree, (3) Neither Agree nor Disagree, (4) Disagree, or (5) Strongly Disagree. The total score ranges from 13 - 65 with higher scores indicating greater difficulty in weighing benefits and burdens of life-sustaining treatments and decision making.
Time Frame
Baseline, 2 Days Post-intervention
Title
Surrogate's Decision Making Confidence (DMC) Scale Score
Description
Surrogate decision-making confidence will be measured using the 5-item Decision Making Confidence (DMC) scale. Surrogates indicate how confident they are about making medical decisions if the patient becomes unable to make their own decisions by their level of agreement with statements along a scale of (0) "Not confident at all" to (5) "Very confident". Total scores range from 0 - 20, with higher scores indicating greater confidence.
Time Frame
Baseline, 2 Days Post-intervention
Secondary Outcome Measure Information:
Title
Care Decisions (Withdrawal From Dialysis, DNR, Hospice Enrollment)
Description
The proportion of decisions (participants who withdrew from dialysis, Do not resuscitate (DNR), or chose hospice enrollment) will be compared between study arms.
Time Frame
6 and 12 Months Post-intervention
Title
Surrogate's Anxiety-Score Using the Hospital Anxiety and Depression Scale (HADS) Score
Description
Surrogate post-bereavement anxiety and depressive symptoms will be measured with the Hospital Anxiety and Depression Scale (HADS). Surrogates indicate their level of agreement with statements by selecting responses rated from 0 (the problem in the statement is not an issue) to 3 (the problem in the statement is a very big issue). The separate anxiety and depression subscale scores range from 0 to 21 with higher scores indicating greater symptom severity. A score of 0-7 indicates "normal", 8-10 indicates "borderline abnormal", and 11-21 indicates "abnormal" levels of anxiety or depression.
Time Frame
Baseline, 1 Month after the Patient's Death
Title
Surrogate's Depression-Score by Using the Hospital Anxiety and Depression Scale (HADS) Score
Description
Surrogate post-bereavement anxiety and depressive symptoms will be measured with the Hospital Anxiety and Depression Scale (HADS). Surrogates indicate their level of agreement with statements by selecting responses rated from 0 (the problem in the statement is not an issue) to 3 (the problem in the statement is a very big issue). The separate anxiety and depression subscale scores range from 0 to 21 with higher scores indicating greater symptom severity. A score of 0-7 indicates "normal", 8-10 indicates "borderline abnormal", and 11-21 indicates "abnormal" levels of anxiety or depression.
Time Frame
Baseline, 1 Month after the Patient's Death
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Patient Inclusion Criteria:
receiving in-center hemodialysis
diagnosed with dementia or having mild to moderate cognitive impairment based on a Montreal Cognitive Assessment (MoCA) score 13-25 or a Saint Louis University Mental Status (SLUMS) score < 27 (high school education) or < 25 (less than high school education)
able to understand and speak English
a University of California San Diego Brief Assessment of Capacity to Consent (UBACC) score of 11 or higher
Exclusion Criteria:
lack of an available surrogate
uncompensated hearing deficits
already enrolled in hospice
Surrogate Inclusion Criteria:
18 years or older
be chosen by the patient
able to understand and speak English
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mi-Kyung Song, RN, PhD
Organizational Affiliation
Emory University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Emory Dialysis at Northside
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30318
Country
United States
Facility Name
Emory Dialysis at Greenbriar
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30331
Country
United States
Facility Name
Emory Dialysis at North Decatur
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30033
Country
United States
Facility Name
Emory Dialysis at Candler
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30034
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
SPIRIT for Persons With Dementia and Complex Multimorbidity
We'll reach out to this number within 24 hrs